Vertex Pharmaceuticals, Inc.

Jeremy J Clemens

Mark Thomas Miller

Jinglan Zhou

Thomas Cleveland

Jason McCartney

Sara Sabina Hadida Ruah

Corey Don Anderson

Timothy Richard Coon

Bryan A Frieman

Haripada Khatuya

Johnny Uy

Prasuna Paraselli

Peter Diederik Jan Grootenhuis

Andreas Peter Termin

Paul Krenitsky

Peter Grootenhuis

Fabrice Jean Denis Pierre

Pramod Virupax Joshi

Raymond Stanley Gross

Alina Silina

Fabrice Pierre

Vito Melillo

Alexander Russell Abela

Sara E Swift

Brian Richard Bear

Vijayalaksmi Arumugam

Hayley Marie Binch

David Andrew Siesel

Yi Shi

Gulin Erdogan Marelius

Paul Angell

Muna Shrestha

Minson Baek

Erica Lynn Conroy

Anton V Gulevich

Clara Kuang-Ju Hsia

Ping Kang

Chun-Chieh Lin

Georgia McGaughey Nicholls

Sara Sabina Hadida-Ruah

Fredrick Van Goor

Robert Michael Hughes

Ali Keshavarz-Shokri

Kathy Stavropoulos

Lori Ann Ferris

Timothy Alcacio

Timothy John Young

Benjamin Joseph Littler

John E Cochran

Beili Zhang

Michel Gallant

Claudio F Sturino

Ales Medek

Brett C Bookser

Thumkunta Jagadeeswar Reddy

Yeeman K Ramtohul

Weichao George Chen

Brett Bradley Busch

Michael Waldo

Kevin Gagnon

Armando Urbina

Carl Zwicker

Brian J Hare

Senait G Ghirmai

Jennifer Lu

Jicong Li

William Schulz Bechara

Julie Laterreur

Carl V Vogel

Yoshihiro Ishihara

Sunny Abraham

Lino J Valdez

Joe Anh Tran

Jaclyn Chau

Timothy A Dwight

Lino Valdez

Jason Mccartney

Claudio Sturino

Bartlomiej Borek

Paul Timothy Angell

David M Altshuler

Patrick R Sosnay

Sarah M Robertson

Reshma Kewalramani

Tim Young

Paul J Krenitsky

Paul John Krenitsky

Fredrick F Van Goor

Tomothy John Young

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

Cystic fibrosis transmembrane conductance regulator modulating agents

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Modulators of cystic fibrosis transmembrane conductance regulator

Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Crystalline forms of CFTR modulators

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R, R, R, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

Process of making CFTR modulators

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof. 

Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.

Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

Growing community of inventors

San Diego, CA, United States of America

Jeremy J Clemens